XML 30 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Related Party Transactions
 3 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

9.

Related Party Transactions

Astellas is an equity investor in the Company and considered a related party. The Company recorded revenue related to collaboration agreements with Astellas of $3.6 million and $4.7 million for the three months ended March 31, 2021 and 2020, respectively.  

During the three months ended March 31, 2021, the Company also recorded drug product revenue from Astellas of $4.0 million related to the API shipments fulfilled under the terms of the Japan Amendment with Astellas in 2018, due to a change in estimated variable consideration. See Note 2, Collaboration Agreements and Revenues, for details.

The Company’s expense related to collaboration agreements with Astellas was $0.1 million for each of the three months ended March 31, 2021 and 2020, respectively.

As of March 31, 2021 and December 31, 2020, accounts receivable from Astellas were $17.5 million and $4.1 million, respectively.

As of March 31, 2021 and December 31, 2020, total deferred revenue from Astellas was $18.6 million and $7.5 million, respectively.

As of March 31, 2021 and December 31, 2020, amounts due to Astellas were $0.1 million and $1.1 million, respectively.

As of March 31, 2021, prepaid expenses and other current assets included $4.0 million of unbilled contract assets from Astellas, representing the above mentioned change in estimated variable consideration related to the API shipments fulfilled in 2018. This amount was billed to Astellas in April 2021. See Note 2, Collaboration Agreements and Revenues, for details.

In September 2020, FibroGen Beijing and AstraZeneca completed the establishment of a jointly owned entity, Falikang, which was determined to be an unconsolidated VIE. As such, Falikang is accounted for as an equity method investment, and considered as a related party to the Company. FibroGen Beijing owns 51.1% of Falikang’s equity. See Note 3, Variable Interest Entity, for details.

For the three months ended March 31, 2021, the net product revenue from Falikang was $10.4 million. See Note 2, Collaboration Agreements and Revenues, for details.

For the three months ended March 31, 2021, the investment loss in Falikang was $0.2 million. As of March 31, 2021 and December 31, 2020, the Company’s equity method investment in Falikang was $2.5 million and $2.7 million, respectively. See Note 3, Variable Interest Entity, for details.

As of March 31, 2021, accounts receivable, net, from Falikang was of $15.4 million.

As of March 31, 2021 and December 31, 2020, prepaid expenses and other current assets included miscellaneous receivables from Falikang of $1.0 million and $0.9 million, respectively.